symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
IMMX,3,0,188545,59043300,0,0.68-4.82,0.03,"Immix Biopharma, Inc.",USD,0001873835,US45258H1068,45258H106,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.immixbio.com,"Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.","Dr. Ilya  Rachman M.B.A., M.D., MBA, Ph.D.",Healthcare,US,9,310 651 8041,11400 West Olympic Boulevard,Los Angeles,CA,90064,,0,https://financialmodelingprep.com/image-stock/IMMX.png,2021-12-16,False,False,True,False,False
